Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786511 · ClinicalTrials.gov registry record
Longterm Follow-up of Subjects Treated With bb2121
A clinical trial of Multiple Myeloma, sponsored by Celgene.
- Completed
- Registry status
- 50
- Enrollment target
- 9
- Study locations
NCT02786511 is a study of Multiple Myeloma that has completed, run by Celgene. The registered enrollment target is 50 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT02786511, a study of Multiple Myeloma, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multi-center, non-randomized, open label, longterm safety and efficacy follow-up study for subjects who have been treated with bb2121 in the Phase 1 clinical parent study, that evaluated the safety and efficacy of bb2121 in subjects with relapsed or refractory B cell maturation antigen (BCMA)-expressing multiple myeloma. bb2121 is defined as autologous T lymphocytes (T cells) transduced ex vivo with anti-BCMA02 CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA suspended in cryopreservative solution. bb2121 is administered in subjects 1 time (or retreated if retreatment criteria are met) in parent clinical study. No investigational treatment will be administered in this study. After completing the parent study, eligible subjects will be followed for up to 15 years after their last bb2121 infusion in the parent study.
Conditions Studied
Interventions
- DRUG Safety and efficacy assessments
Study Locations (9)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
California
- Stanford Cancer Center - Palo Alto
Maryland
- National Cancer Institute - Bethesda
Minnesota
- Mayo Clinic Cancer Center - Rochester
New Jersey
- Hackensack University Medical Center - Hackensack
New York
- Mount Sinai Medical Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-04-28 |
| Est. Completion | 2019-10-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02786511
The ClinicalTrials.gov registry entry for NCT02786511 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Safety and efficacy assessments is the first listed.
NCT02786511 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Massachusetts, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT02786511 about?
NCT02786511 is a clinical study titled "Longterm Follow-up of Subjects Treated With bb2121". This is a multi-center, non-randomized, open label, longterm safety and efficacy follow-up study for subjects who have been treated with bb2121 in the Phase 1 clinical parent study, that evaluated the safety and efficacy of bb2121 in subjects with relapsed or refractory B cell maturation antigen (BC...
What is the current status of trial NCT02786511?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2016-04-28. Estimated completion is 2019-10-11.
What conditions does trial NCT02786511 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT02786511?
The interventions under investigation include: Safety and efficacy assessments (DRUG).
Who is sponsoring clinical trial NCT02786511?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02786511 being conducted?
This trial has 9 study locations across California, Maryland, Massachusetts, Minnesota, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.